These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 26684558)

  • 41. [PCSK9 inhibitors - new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated?Czech atherosclerosis society statement].
    Soška V; Vrablík M; Bláha V; Cífková R; Češka R; Freiberger T; Kraml P; Piťha J; Rosolová H; Štulc T; Vaverková H; Urbanová Z
    Vnitr Lek; 2016 Apr; 62(4):329-33. PubMed ID: 27250613
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
    Shen L; Peng H; Xu D; Zhao S
    Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The promise of proprotein convertase subtilisin/kexin 9 inhibitors for the treatment of familial hypercholesterolemia.
    Pokharel Y; Virani SS; Ballantyne CM
    Curr Atheroscler Rep; 2015 May; 17(5):508. PubMed ID: 25782778
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recent advances in the pharmacological management of hypercholesterolaemia.
    Ajufo E; Rader DJ
    Lancet Diabetes Endocrinol; 2016 May; 4(5):436-46. PubMed ID: 27012540
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Treating hypercholesterolemia - when and how].
    Vogt A
    Dtsch Med Wochenschr; 2015 Oct; 140(20):1490-3. PubMed ID: 26445250
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Stein EA; Dufour R; Turner T; Civeira F; Burgess L; Langslet G; Scott R; Olsson AG; Sullivan D; Hovingh GK; Cariou B; Gouni-Berthold I; Somaratne R; Bridges I; Scott R; Wasserman SM; Gaudet D;
    Lancet; 2015 Jan; 385(9965):331-40. PubMed ID: 25282519
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment].
    Češka R; Štulc T; Votavová L; Schwarzová L; Vaclová M; Freiberger T
    Vnitr Lek; 2016; 62(11):887-894. PubMed ID: 28128575
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.
    Tavori H; Melone M; Rashid S
    Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1137-44. PubMed ID: 25244623
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia.
    Lee P; Hegele RA
    Expert Opin Investig Drugs; 2013 Nov; 22(11):1411-23. PubMed ID: 23889692
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
    Arca M
    Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.
    Stein EA; Honarpour N; Wasserman SM; Xu F; Scott R; Raal FJ
    Circulation; 2013 Nov; 128(19):2113-20. PubMed ID: 24014831
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Familial Hypercholesterolemia: Advances in Recognition and Therapy.
    Cartier JL; Goldberg AC
    Prog Cardiovasc Dis; 2016; 59(2):125-134. PubMed ID: 27477957
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mipomersen and its use in familial hypercholesterolemia.
    Parham JS; Goldberg AC
    Expert Opin Pharmacother; 2019 Feb; 20(2):127-131. PubMed ID: 30526168
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies.
    Sniderman AD; Tsimikas S; Fazio S
    J Am Coll Cardiol; 2014 May; 63(19):1935-47. PubMed ID: 24632267
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
    Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M
    J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies.
    El Khoury P; Elbitar S; Ghaleb Y; Khalil YA; Varret M; Boileau C; Abifadel M
    Curr Atheroscler Rep; 2017 Oct; 19(12):49. PubMed ID: 29038906
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of PCSK9 Inhibitors in High Risk Patients with Dyslipidemia: Focus on Familial Hypercholesterolemia.
    Papademetriou V; Stavropoulos K; Papadopoulos C; Koutsampasopoulos K; Dimitriadis K; Tsioufis K
    Curr Pharm Des; 2018; 24(31):3647-3653. PubMed ID: 30317985
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacogenetics in the Development of Lipid Lowering Medications: Lomitapide & Mipomersen in Clinical Practice.
    Marbach JA; Thapa J; Goldenberg E; Duffy D
    Del Med J; 2015 Aug; 87(8):238-43. PubMed ID: 26402926
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives.
    Catapano AL; Pirillo A; Norata GD
    Vasc Health Risk Manag; 2017; 13():343-351. PubMed ID: 28919772
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.